Disposition of 49701 shares by Michael Wortley of Reata Pharmaceuticals subject to Rule 16b-3
| FRBRX Fund | USD 147.44 1.08 0.74% |
Slightly above 53% of Franklin Biotechnology's investor base is interested to short. The analysis of overall sentiment of trading Franklin Biotechnology Discovery mutual fund suggests that many investors are impartial at this time. Franklin Biotechnology's investing sentiment can be driven by a variety of factors including economic data, Franklin Biotechnology's earnings reports, geopolitical events, and overall market trends.
Franklin |
Filed transaction by Reata Pharmaceuticals Inc officer. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
Read at macroaxis.com
Franklin Biotechnology Fundamental Analysis
We analyze Franklin Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Franklin Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Franklin Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this mutual fund, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Ten Year Return
Ten Year Return Comparative Analysis
Franklin Biotechnology is currently under evaluation in ten year return among similar funds. Ten Year Return shows the total annualized return generated from holding a fund for the last 10 years and represents fund's capital appreciation, including dividends losses and capital gains distributions. This return indicator is considered by many investors to be the ultimate measures of fund performance and can reflect the overall performance of the market or market segment it invests in.
Franklin Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Franklin Biotechnology mutual fund to make a market-neutral strategy. Peer analysis of Franklin Biotechnology could also be used in its relative valuation, which is a method of valuing Franklin Biotechnology by comparing valuation metrics with similar companies.
Peers
Franklin Biotechnology Related Equities
| TEBIX | Franklin Mutual | 0.53 |
| ||
| TEDSX | Franklin Mutual | 0.54 |
| ||
| TEDRX | Franklin Mutual | 0.55 |
| ||
| TEGBX | Templeton Global | 0.59 |
| ||
| TEGRX | Templeton Growth | 0.64 |
| ||
| TEFRX | Templeton Foreign | 0.64 |
| ||
| TEDIX | Franklin Mutual | 0.64 |
| ||
| TEMFX | Templeton Foreign | 0.75 |
| ||
| TEDMX | Templeton Developing | 0.91 |
| ||
| TEFTX | Templeton Foreign | 1.11 |
|
Other Information on Investing in Franklin Mutual Fund
Franklin Biotechnology financial ratios help investors to determine whether Franklin Mutual Fund is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Franklin with respect to the benefits of owning Franklin Biotechnology security.
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Global Correlations Find global opportunities by holding instruments from different markets | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Fundamental Analysis View fundamental data based on most recent published financial statements |